<DOC>
	<DOCNO>NCT00382629</DOCNO>
	<brief_summary>The purpose study determine BHT-3009 decrease inflammation ( measured gadolinium enhance MRI lesion ) brain people relapse remit multiple sclerosis .</brief_summary>
	<brief_title>BHT-3009 Immunotherapy Relapsing Remitting Multiple Sclerosis</brief_title>
	<detailed_description>People multiple sclerosis think abnormal immunity . Usually body 's immune system attack foreign substance , people MS abnormal immunity , immune system attack normal protein , one protein find brain call MBP ( myelin basic protein ) . This abnormal immunity cause inflammation brain result nerve damage . BHT-3009 drug design decrease abnormal immunity MBP . BHT-3009 DNA plasmid contain gene MBP . Plasmids circular piece DNA test clinical trial ability alter patient ' immune system . Two different dos BHT-3009 test determine difference safety effect inflammation . Treatment study 3 dos every two week 6 week , follow dose every 4 week total 13 dos 44 week .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>1 . Definite diagnosis multiple sclerosis McDonald criterion . 2 . Screening cranial MRI demonstrate lesion consistent MS. 3 . One relapse within previous year . 4 . Clinically stable ( relapse ) &gt; 50 day begin screen procedure screen period . 5 . EDSS 0 3.5 inclusive . 6 . Age &gt; 17 year &lt; 56 year . 7 . Willing able give inform consent . 8 . WBC &gt; 3,000 ; platelet &gt; 100,000 ; hemoglobin &gt; 10.0 g/dl . 9 . AST , ALT , bilirubin &lt; 2.0 x upper limit normal . 10 . Creatinine &lt; 2.0 x upper limit normal . 11 . Negative test HIV . 1 . Primary progressive , secondary progressive progressive relapse MS. 2 . More 5 gadoliniumenhancing lesion first screen MRI . 3 . Highdose corticosteroid ( e.g . &gt; 500 mg methylprednisolone equivalent per day 3 day ) within 50 day prior begin screen procedure . 4 . Previous stem cell transplantation , total lymphoid radiation , cytotoxic therapy . 5 . Treatment interferon , glatiramer acetate approve diseasemodifying agent &gt; 180 day ( lifetime total agent ) . 6 . Treatment approve disease modify agent within 180 day begin screening procedure . 7 . Previous treatment MS experimental agent include offlabel use approve drug . ( Allowed approval Medical Monitor . ) 8 . Prior therapy natalizumab ( Tysabri ) . 9 . Pregnant lactating woman . 10 . Unwilling use medically acceptable form birth control ( e.g . hormonal contraception , intrauterine device , double barrier , sterilization self partner ) . 11 . Clinically significant ECG abnormality ( e.g . acute ischemia lifethreatening arrhythmia ) . 12 . Medical condition social circumstance would opinion investigator prevent full participation trial evaluation study endpoint . 13 . Implanted pace maker , defibrillator metallic object inside body limit perform MRI scan . 14 . Known hypersensitivity allergy gadolinium .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Bayhill</keyword>
	<keyword>BHT-3009</keyword>
	<keyword>immunotherapy</keyword>
</DOC>